Outcomes over the first two years of treatment with mepolizumab in severe asthma

Lynn Elsey; Thomas Pantin; Leanne-Jo Holmes; Gael Tavernier; Stephen J Fowler

doi:10.1183/13993003.01313-2021

Outcomes over the first two years of treatment with mepolizumab in severe asthma

Lynn Elsey, Thomas Pantin, Leanne-Jo Holmes, Gael Tavernier, Stephen J Fowler

Division of Immunology, Immunity to Infection and Respiratory Medicine

Manchester University NHS Foundation Trust

Research output: Contribution to journal › Article › peer-review

Abstract

Almost a third of our patients with severe asthma did not have continued benefit from mepolizumab in the second year of treatment. Those with a sustained response had lower blood eosinophils and better asthma control questionnaire scores prior to starting mepolizumab.

Original language	English
Journal	The European respiratory journal
Early online date	28 Oct 2021
DOIs	https://doi.org/10.1183/13993003.01313-2021
Publication status	E-pub ahead of print - 28 Oct 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1183/13993003.01313-2021

Cite this

@article{34af9089f5f346a68a0ab708f9c2e71c,

title = "Outcomes over the first two years of treatment with mepolizumab in severe asthma",

abstract = "Almost a third of our patients with severe asthma did not have continued benefit from mepolizumab in the second year of treatment. Those with a sustained response had lower blood eosinophils and better asthma control questionnaire scores prior to starting mepolizumab.",

author = "Lynn Elsey and Thomas Pantin and Leanne-Jo Holmes and Gael Tavernier and Fowler, \{Stephen J\}",

note = "Copyright {\textcopyright}The authors 2021. For reproduction rights and permissions contact [email protected].",

year = "2021",

month = oct,

day = "28",

doi = "10.1183/13993003.01313-2021",

language = "English",

journal = "The European respiratory journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

}

TY - JOUR

T1 - Outcomes over the first two years of treatment with mepolizumab in severe asthma

AU - Elsey, Lynn

AU - Pantin, Thomas

AU - Holmes, Leanne-Jo

AU - Tavernier, Gael

AU - Fowler, Stephen J

PY - 2021/10/28

Y1 - 2021/10/28

N2 - Almost a third of our patients with severe asthma did not have continued benefit from mepolizumab in the second year of treatment. Those with a sustained response had lower blood eosinophils and better asthma control questionnaire scores prior to starting mepolizumab.

AB - Almost a third of our patients with severe asthma did not have continued benefit from mepolizumab in the second year of treatment. Those with a sustained response had lower blood eosinophils and better asthma control questionnaire scores prior to starting mepolizumab.

UR - https://www.scopus.com/pages/publications/85122865187

U2 - 10.1183/13993003.01313-2021

DO - 10.1183/13993003.01313-2021

M3 - Article

C2 - 34711539

SN - 0903-1936

JO - The European respiratory journal

JF - The European respiratory journal

ER -

Outcomes over the first two years of treatment with mepolizumab in severe asthma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this